Dossier assessment
Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with multiple myeloma who have received at least one prior therapy
Added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021.07.15 A G-BA decision was published.
Project details
- Project no.
- A21-08
- Commission
- Commission awarded on 15.01.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Carfilzomib (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Carfilzomib (multiple myeloma; combination with dexamethasone alone) – Assessment according to § 35a (para. 1, sentence 10) Social Code Book V
Status: Commission completed
-
Dossier assessment
Carfilzomib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Status: Commission completed
-
Addendum
Carfilzomib (multiple myeloma) - Addendum to Commission A21-08
Status: Commission completed